TNF Pharmaceuticals, Inc.
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rh… Read more
TNF Pharmaceuticals, Inc. (TNFA) - Total Assets
Latest total assets as of June 2025: $17.15 Million USD
Based on the latest financial reports, TNF Pharmaceuticals, Inc. (TNFA) holds total assets worth $17.15 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TNF Pharmaceuticals, Inc. - Total Assets Trend (2004–2024)
This chart illustrates how TNF Pharmaceuticals, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TNF Pharmaceuticals, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
TNF Pharmaceuticals, Inc.'s total assets of $17.15 Million consist of 43.9% current assets and 56.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $10.50 Million | 49.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how TNF Pharmaceuticals, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TNF Pharmaceuticals, Inc.'s current assets represent 43.9% of total assets in 2024, a decrease from 75.9% in 2004.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 12.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 7.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 49.0% of total assets.
TNF Pharmaceuticals, Inc. Competitors by Total Assets
Key competitors of TNF Pharmaceuticals, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
TNF Pharmaceuticals, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TNF Pharmaceuticals, Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TNF Pharmaceuticals, Inc. is currently not profitable relative to its asset base.
TNF Pharmaceuticals, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 2.48 | 0.02 |
| Quick Ratio | 0.93 | 2.48 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-397.58K | $ 8.57 Million | $ -2.73 Million |
TNF Pharmaceuticals, Inc. - Advanced Valuation Insights
This section examines the relationship between TNF Pharmaceuticals, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.84 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | 19.9% |
| Total Assets | $21.42 Million |
| Market Capitalization | $6.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values TNF Pharmaceuticals, Inc.'s assets below their book value (0.30 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: TNF Pharmaceuticals, Inc.'s assets grew by 19.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TNF Pharmaceuticals, Inc. (2004–2024)
The table below shows the annual total assets of TNF Pharmaceuticals, Inc. from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $21.42 Million | +19.92% |
| 2023-12-31 | $17.86 Million | +1.84% |
| 2022-12-31 | $17.54 Million | -29.31% |
| 2021-12-31 | $24.81 Million | -32.65% |
| 2020-12-31 | $36.84 Million | +238.47% |
| 2019-12-31 | $10.88 Million | +39.42% |
| 2018-12-31 | $7.81 Million | -16.39% |
| 2017-12-31 | $9.34 Million | +83.63% |
| 2016-12-31 | $5.09 Million | -38.53% |
| 2015-12-31 | $8.27 Million | -50.32% |
| 2014-12-31 | $16.65 Million | +174.06% |
| 2013-12-31 | $6.08 Million | -5.32% |
| 2012-12-31 | $6.42 Million | -6.77% |
| 2011-12-31 | $6.88 Million | -10.80% |
| 2010-12-31 | $7.72 Million | -7.34% |
| 2009-12-31 | $8.33 Million | -26.13% |
| 2008-12-31 | $11.27 Million | +59.79% |
| 2007-12-31 | $7.06 Million | +134.96% |
| 2006-12-31 | $3.00 Million | -63.53% |
| 2005-12-31 | $8.24 Million | +455.70% |
| 2004-12-31 | $1.48 Million | -- |